WO2012131650A1 - Herbal compositions of coccinia indica for treatment or prevention of inflammatory diseases - Google Patents
Herbal compositions of coccinia indica for treatment or prevention of inflammatory diseases Download PDFInfo
- Publication number
- WO2012131650A1 WO2012131650A1 PCT/IB2012/051580 IB2012051580W WO2012131650A1 WO 2012131650 A1 WO2012131650 A1 WO 2012131650A1 IB 2012051580 W IB2012051580 W IB 2012051580W WO 2012131650 A1 WO2012131650 A1 WO 2012131650A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- herbal compositions
- indica
- coccinia
- coccinia indica
- chronic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 240000006560 Coccinia grandis Species 0.000 title claims abstract description 42
- 235000006165 Coccinia grandis Nutrition 0.000 title claims abstract description 42
- 208000027866 inflammatory disease Diseases 0.000 title claims abstract description 20
- 230000002265 prevention Effects 0.000 title claims abstract description 20
- 235000006491 Acacia senegal Nutrition 0.000 claims description 13
- 235000006509 Acacia nilotica Nutrition 0.000 claims description 12
- 235000003911 Arachis Nutrition 0.000 claims description 12
- 244000105624 Arachis hypogaea Species 0.000 claims description 12
- 244000154674 Diospyros ebenaster Species 0.000 claims description 12
- 235000008041 Diospyros ebenaster Nutrition 0.000 claims description 12
- 235000007901 Diospyros malabarica Nutrition 0.000 claims description 12
- 240000007228 Mangifera indica Species 0.000 claims description 12
- 235000014826 Mangifera indica Nutrition 0.000 claims description 12
- 244000191761 Sida cordifolia Species 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- 235000008216 herbs Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 2
- 206010008617 Cholecystitis chronic Diseases 0.000 claims description 2
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000014085 Chronic respiratory disease Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 206010014666 Endocarditis bacterial Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000012659 Joint disease Diseases 0.000 claims description 2
- 201000008197 Laryngitis Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010036030 Polyarthritis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000009361 bacterial endocarditis Diseases 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 208000007451 chronic bronchitis Diseases 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 208000018631 connective tissue disease Diseases 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 239000000284 extract Substances 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 201000007119 infective endocarditis Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000015001 muscle soreness Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 206010035653 pneumoconiosis Diseases 0.000 claims description 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- 244000215188 Acacia nilotica Species 0.000 claims 4
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 208000004396 mastitis Diseases 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 4
- 244000215068 Acacia senegal Species 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229910001868 water Inorganic materials 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PTTPXKJBFFKCEK-UHFFFAOYSA-N 2-Methyl-4-heptanone Chemical compound CC(C)CC(=O)CC(C)C PTTPXKJBFFKCEK-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000033678 Thelitis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- Inflammation is a complex reaction of the body responding to damage of its cells and vascularised tissues.
- the damaged sites are susceptible to infiltration by a multitude of pathogens including viruses, bacteria, fungi, and protozoan and metazoan parasites, as well as cancerous cells and other harmful agents and so the animal defends itself by initiating an inflammatory reaction at the damaged site.
- Mastitis in which there is inflation of the mammary gland, and is mainly caused by bacteria. It is commonly observed in dairy cattle such as cows and goats.
- NSAIDs non-steroidal anti-inflammatory drugs
- Diclofenac diclofenac
- Ibuprofen Aspirin
- Phenylbutazone Indomethacin
- Naproxen Naproxen
- Piroxicam non-steroidal anti-inflammatory drugs
- the object of the invention is to provide novel herbal compositions which may be cost effective and easily available for treatment or prevention of inflammatory diseases such as mastitis, and which have less or no side effects to the health of a subject.
- the present invention in a preferred embodiment provides herbal compositions for treatment or prevention of inflammatory diseases such as mastitis, comprising of at least a part of Coccinia indica, to which parts of one or more additional complimentary herb may be optionally added, wherein the additional complimentary herb is also a herb for treatment or prevention of inflammatory diseases such as mastitis, and is selected from but not limited to Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia, or any combination thereof.
- the invention also provides for methods of preparation of the herbal compositions.
- the present invention in a preferred embodiment provides herbal compositions for treatment or prevention of inflammatory diseases such as mastitis, comprising of at least a part of Coccinia indica, to which parts of one or more additional complimentary herb may be optionally added, wherein the additional complimentary herb is also a herb for treatment or prevention of inflammatory diseases such as mastitis, and is selected from but not limited to Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia, or any combination thereof.
- Parts of Coccinia indica for the purpose of this invention includes the whole Coccinia indica, extract of Coccinia indica, pulverized form of Coccinia indica, crushed form of Coccinia indica, pieces cut or severed from Coccinia indica, chemical constituents of Coccinia indica along with their derivatives, or any combination thereof.
- parts of Coccinia indica are severed by different methods such as but not limited to cutting, slicing, pounding, grinding, mashing or mincing.
- composition' for the purpose of this invention means a substance or mixture comprising of at least one natural component having medicinal property, wherein the natural component shall include a component extracted or derived from a natural source such as a herb or a plant or a tree or parts thereof.
- the term subject for the purpose of the invention means one or more of a human or any other animal which has acquired or may acquire a disease or irregularity of health.
- the herbs used for the compositions in accordance with the present invention shall include other herbs of their respective species or family or genus which display similar medicinal properties.
- a solvent may be used for preparing the herbal compositions of the present invention, and the solvent used may be any suitable solvent such as but not limited to one or more of methanol, ethanol, n-propanol, isopropanol, hexane, heptane, petroleum ether, cyclohexane, diethyl ether, dusopropyl ether, ethyl acetate, methyl acetate, ethyl formate, methyl formate, isobutyl acetate, n-butyl acetate, methylene chloride, ethylene chloride, chloroform, carbon tetrachloride, acetone, ethyl methyl ketone, diisobutyl ketone, methyl isobutyl ketone, 1,4- dioxane, toluene, ammonia solution, glacial acetic acid, ammonium hydroxide, sodium hydroxide, calcium hydroxide
- a suitable excipient is added to the herbal compositions of the present invention to prepare a consumable formulation for effective therapeutic delivery.
- the herbal compositions of the present invention may be formulated for oral administration by compounding the active ingredients with the usual nontoxic pharmaceutically acceptable excipients for tablets, pellets, granules, capsules, solutions, emulsions, suspensions, and any other form suitable for use.
- Formulations in accordance with the present invention may include one or more of talc, water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, corn starch, keratin, colloidal silica, potato starch, urea, and other excipients suitable for use in manufacturing preparations, in solid, semisolid or liquid form, or any combination thereof.
- auxiliary, stabilizing, thickening, flavoring, fragrance and coloring agents may be used.
- the herbal compositions can be administered in a solid form such as but not limited to tablets, capsules, pills, pellets, granules, boluses or powder.
- a solid form such as but not limited to tablets, capsules, pills, pellets, granules, boluses or powder.
- the herbal compositions may be mixed with a pharmaceutical excipient such as but not limited to corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, along with other pharmaceutical diluents.
- the solid compositions may be further subdivided into unit dosage forms containing an effective amount of compositions of the present invention.
- the herbal compositions can be administered in a liquid form such as but not limited to aqueous solution, suitably flavored syrups, aqueous suspensions, oil suspensions, tinctures, tisanes, macerates and flavored emulsions with edible oils as well as elixirs or similar pharmaceutical carriers.
- the liquid form may include suitable dispersing or suspending agents for aqueous suspensions such as but not limited to tragacanth, acacia, alginate, dextran, sodium carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for reconstitution with water or other suitable vehicles before use.
- a process for preparing herbal compositions for treatment or prevention of inflammatory disease comprises the steps of,
- a process for preparing herbal compositions for treatment or prevention of inflammatory disease comprises the steps of,
- a process for preparing herbal compositions for treatment or prevention of inflammatory disease comprises the steps of,
- a process for preparing herbal compositions for treatment or prevention of inflammatory disease comprises the steps of,
- the herbal compositions may be delivered as a semi-solid form or gelatinous solid, such as but not limited to paste, jelly, gel or chutney.
- the herbal compositions may be delivered as a gaseous form or in form of aerosols which includes but not limited to spray, fumes, inhalers or mist.
- the herbal compositions may also be formulated for parenteral administration by injection, which includes but is not limited to using conventional catheterization techniques or infusion.
- the herbal compositions may also be formulated for topical administration, in the form of solution, cream, gel, ointment, powder, paste, gum or lozenge, using techniques known to those skilled in the formulation field.
- topical administration includes delivery of the compositions to mucosal tissue of the mouth, nose and throat by, for example, spray or mist application.
- the herbal compositions as an active ingredient may be used alone or in combination with other therapeutic agents, for treatment or prevention of inflammatory diseases such as mastitis.
- a part of Coccinia indica is added to or mixed with fodder provided to cattle and administered orally to the subject.
- a part of Coccinia indica is added to or mixed with water and administered orally to the subject.
- the herbal compositions of the present invention may be in the form of a decoction or may be prepared using a decoction process.
- a part of Coccinia indica can be given chemical treatment or made to react with other chemical reagents to form mixtures or herbal compositions which are used for treatment or prevention of inflammatory diseases such as mastitis.
- the desirable dose of the compositions may vary depending on the condition and the weight of the subject, severity, drug form, route and period of administration.
- the herbal composition may be used for treatment or prevention of mastitis.
- the herbal composition may be used for treatment or prevention of a inflammatory condition other than mastitis that may be selected from the group consisting of, but not limited to inflammatory joint diseases, rheumatoid arthritis, osteoarthritis, polyarthritis, gout, chronic inflammatory connective tissue diseases, lupus erythematosus, scleroderma, Sjorgen's syndrome, dermatomyositis, vasculitis, mixed connective tissue disease, tendonitis, synovitis, bacterial endocarditis, osteomyelitis and psoriasis, chronic inflammatory lung diseases, chronic respiratory disease, pneumonia, fibrosing alveolitis, chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, emphysema, silicosis and other pneumoconiosis, tuberculosis, chronic inflammatory bowel, gastro-intestinal tract inflammatory diseases, chronic inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention in a preferred embodiment provides for herbal compositions for treatment or prevention of inflammatory diseases such as mastitis. The present invention also provides for the methods of preparation and various forms of administration of the said compositions. The said compositions comprise of at least a part of Coccinia indica.
Description
HERBAL COMPOSITIONS OF COCCINIA INDICA FOR TREATMENT OR PREVENTION OF
INFLAMMATORY DISEASES
BACKGROUND:
Inflammation is a complex reaction of the body responding to damage of its cells and vascularised tissues. The damaged sites are susceptible to infiltration by a multitude of pathogens including viruses, bacteria, fungi, and protozoan and metazoan parasites, as well as cancerous cells and other harmful agents and so the animal defends itself by initiating an inflammatory reaction at the damaged site.
There is a vast array of diseases exhibiting an inflammatory component. Among these diseases is Mastitis, in which there is inflation of the mammary gland, and is mainly caused by bacteria. It is commonly observed in dairy cattle such as cows and goats.
The usual mode of treatment for chronic inflammatory conditions is by administration of non-steroidal anti-inflammatory drugs (NSAIDs) such as Diclofenac, Ibuprofen, Aspirin, Phenylbutazone, Indomethacin, Naproxen and Piroxicam. Although NSAIDs and other the synthetic medicines and associated treatment methods pose the threat of side effects and chemical toxicity which can adversely affect a subject's overall health, and mostly involve high cost and effort in manufacturing.
Considering the significance of treatment or prevention of inflammatory diseases such as mastitis, there is a continuous requirement for medicines or compositions for their treatment or prevention, which would be economical, easily available and may have lower side effects and lower toxicities affecting a subject's body, which can be addressed by herbal compositions of the present invention.
OBJECT OF THE INVENTION:
The object of the invention is to provide novel herbal compositions which may be cost effective and easily available for treatment or prevention of inflammatory diseases such as mastitis, and which have less or no side effects to the health of a subject.
SUMMARY OF THE INVENTION:
The present invention in a preferred embodiment provides herbal compositions for treatment or prevention of inflammatory diseases such as mastitis, comprising of at least a part of Coccinia indica, to which parts of one or more additional complimentary herb may be optionally added, wherein the additional complimentary herb is also a herb for treatment or prevention of inflammatory diseases such as mastitis, and is selected from but not limited to Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia, or any combination thereof. The invention also provides for methods of preparation of the herbal compositions.
DETAIL DESCRITION OF THE INVENTION:
The present invention in a preferred embodiment provides herbal compositions for treatment or prevention of inflammatory diseases such as mastitis, comprising of at least a part of Coccinia indica, to which parts of one or more additional complimentary herb may be optionally added, wherein the additional complimentary herb is also a herb for treatment or prevention of inflammatory diseases such as mastitis, and is selected from but not limited to Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia, or any combination thereof.
Parts of Coccinia indica for the purpose of this invention includes the whole Coccinia indica, extract of Coccinia indica, pulverized form of Coccinia indica, crushed form of Coccinia indica, pieces cut or severed from Coccinia indica, chemical constituents of Coccinia indica along with their derivatives, or any combination thereof.
In an embodiment of the invention, parts of Coccinia indica are severed by different methods such as but not limited to cutting, slicing, pounding, grinding, mashing or mincing.
The term 'herbal composition' for the purpose of this invention means a substance or mixture comprising of at least one natural component having medicinal property, wherein the natural component shall include a component extracted or derived from a natural source such as a herb or a plant or a tree or parts thereof.
The term subject for the purpose of the invention means one or more of a human or any other animal which has acquired or may acquire a disease or irregularity of health.
The herbs used for the compositions in accordance with the present invention, shall include other herbs of their respective species or family or genus which display similar medicinal properties.
In an embodiment of the invention a solvent may be used for preparing the herbal compositions of the present invention, and the solvent used may be any suitable solvent such as but not limited to one or more of methanol, ethanol, n-propanol, isopropanol, hexane, heptane, petroleum ether, cyclohexane, diethyl ether, dusopropyl ether, ethyl acetate, methyl acetate, ethyl formate, methyl formate, isobutyl acetate, n-butyl acetate, methylene chloride, ethylene chloride, chloroform, carbon tetrachloride, acetone, ethyl methyl ketone, diisobutyl ketone, methyl isobutyl ketone, 1,4- dioxane, toluene, ammonia solution, glacial acetic acid, ammonium hydroxide, sodium hydroxide, calcium hydroxide, calcium carbonate, potassium hydroxide, potassium carbonate, water and other solvents known by those of skilled in the art.
In an embodiment of the invention, a suitable excipient is added to the herbal compositions of the present invention to prepare a consumable formulation for effective therapeutic delivery.
In an embodiment of the invention, the herbal compositions of the present invention may be formulated for oral administration by compounding the active ingredients with the usual nontoxic pharmaceutically acceptable excipients for tablets, pellets, granules, capsules, solutions, emulsions, suspensions, and any other form suitable for use. Formulations in accordance with the present invention may include one or more of talc, water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, corn starch, keratin, colloidal silica, potato starch, urea, and other excipients suitable for use in manufacturing preparations, in solid, semisolid or liquid form, or any combination thereof. Additionally, auxiliary, stabilizing, thickening, flavoring, fragrance and coloring agents may be used.
In an embodiment of the invention, the herbal compositions can be administered in a solid form such as but not limited to tablets, capsules, pills, pellets, granules, boluses or powder. For preparing the solid form, the herbal compositions may be mixed with a pharmaceutical excipient such as but not limited to corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, along with other pharmaceutical diluents.
The solid compositions may be further subdivided into unit dosage forms containing an effective amount of compositions of the present invention.
In an embodiment of the invention, the herbal compositions can be administered in a liquid form such as but not limited to aqueous solution, suitably flavored syrups, aqueous suspensions, oil suspensions, tinctures, tisanes, macerates and flavored emulsions with edible oils as well as elixirs or similar pharmaceutical carriers. The liquid form may include suitable dispersing or suspending agents for aqueous suspensions such as but not limited to tragacanth, acacia, alginate, dextran, sodium carboxymethyl cellulose, methylcellulose, polyvinylpyrrolidone or gelatin. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for reconstitution with water or other suitable vehicles before use.
In an embodiment of the invention, a process for preparing herbal compositions for treatment or prevention of inflammatory disease, comprises the steps of,
a) washing a part of Coccinia indica;
b) sieving the part of Coccinia indica; and
c) preparing pharmaceutically acceptable formulation thereof.
In an embodiment of the invention, a process for preparing herbal compositions for treatment or prevention of inflammatory disease, comprises the steps of,
a) washing a part of Coccinia indica and a part of an additional herb; b) sieving the part of Coccinia indica and the part of the additional herb; c) mixing the part of Coccinia indica and the part of the additional herb; and d) preparing pharmaceutically acceptable formulation thereof.
In an embodiment of the invention, a process for preparing herbal compositions for treatment or prevention of inflammatory disease, comprises the steps of,
a) washing a part of Coccinia indica and a part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia;
b) sieving the part of Coccinia indica and the part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia;
c) mixing the part of Coccinia indica and the part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia;
d) heating the above mixture in a vessel containing a solvent; and
e) preparing pharmaceutically acceptable formulation thereof.
In an embodiment of the invention, a process for preparing herbal compositions for treatment or prevention of inflammatory disease, comprises the steps of,
a) washing a part of root of Coccinia indica and a part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia;
b) sieving the part of root of Coccinia indica and the part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia;
c) mixing 40 to 60% of the part of root of Coccinia indica and 50 to 60% of the part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia; and
d) heating the above mixture in a vessel containing a solvent; and
e) preparing pharmaceutically acceptable formulation thereof.
In an embodiment of the invention, the herbal compositions may be delivered as a semi-solid form or gelatinous solid, such as but not limited to paste, jelly, gel or chutney.
In an embodiment of the invention, the herbal compositions may be delivered as a gaseous form or in form of aerosols which includes but not limited to spray, fumes, inhalers or mist.
In an embodiment of the invention, the herbal compositions may also be formulated for parenteral administration by injection, which includes but is not limited to using conventional catheterization techniques or infusion.
In an embodiment of the invention, the herbal compositions may also be formulated for topical administration, in the form of solution, cream, gel, ointment, powder, paste, gum or lozenge, using techniques known to those skilled in the formulation field. As used herein,
topical administration includes delivery of the compositions to mucosal tissue of the mouth, nose and throat by, for example, spray or mist application.
In an embodiment of the invention, the herbal compositions as an active ingredient may be used alone or in combination with other therapeutic agents, for treatment or prevention of inflammatory diseases such as mastitis.
In an embodiment of the invention, a part of Coccinia indica is added to or mixed with fodder provided to cattle and administered orally to the subject.
In an embodiment of the invention, a part of Coccinia indica is added to or mixed with water and administered orally to the subject.
In an embodiment of the invention, the herbal compositions of the present invention may be in the form of a decoction or may be prepared using a decoction process.
In an embodiment of the invention a part of Coccinia indica can be given chemical treatment or made to react with other chemical reagents to form mixtures or herbal compositions which are used for treatment or prevention of inflammatory diseases such as mastitis.
In an embodiment of the invention, the desirable dose of the compositions may vary depending on the condition and the weight of the subject, severity, drug form, route and period of administration.
In an embodiment of the invention, the herbal composition may be used for treatment or prevention of mastitis.
In an embodiment of the invention, the herbal composition may be used for treatment or prevention of a inflammatory condition other than mastitis that may be selected from the group consisting of, but not limited to inflammatory joint diseases, rheumatoid arthritis, osteoarthritis, polyarthritis, gout, chronic inflammatory connective tissue diseases, lupus erythematosus, scleroderma, Sjorgen's syndrome, dermatomyositis, vasculitis, mixed connective tissue disease, tendonitis, synovitis, bacterial endocarditis, osteomyelitis and psoriasis, chronic inflammatory lung diseases, chronic respiratory disease, pneumonia,
fibrosing alveolitis, chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, emphysema, silicosis and other pneumoconiosis, tuberculosis, chronic inflammatory bowel, gastro-intestinal tract inflammatory diseases, chronic inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, Guillan-Barre Syndrome and myasthemia gravis, laminitis, laryngitis, chronic cholecystitis, Hashimoto's thyroiditis, chronic inflammation caused by an implanted foreign body in a wound, delayed onset muscle soreness, or any combination thereof.
It is observed that when more than one herb is used in the herbal compositions of the present invention, there is enhanced efficacy and the combination of herbs lead to synergistic effect.
The aim of this specification is to describe the invention without limiting the invention to any one embodiment or specific collection of features. A person skilled in the relevant art may realize the variations from the specific embodiments that will nonetheless fall within the scope of the invention, and such variations are deemed to be within the scope of the current invention.
It may be appreciated that various other modifications and changes may be made to the embodiment described without departing from the spirit and scope of the invention.
Example
Clinical cases were evaluated on bacterial proliferation, tissue irritation and nature of milk. The impact of the formulation was evaluated by isolating Bacterial culture and efficacy testing in affected quarter. Tissue irritation was studied by physical examination and clinical observation by quantifying parameters like swelling, erthema and pain/hot. The nature of milk was examined by including variables like not normal, apparently normal, hemorrhagic, curdled milk, flakes, serous, thelitis in-order of severity of infection. The medication relieved the affected animals within 2 days.
Claims
I CLAIM:
1) Herbal compositions for treatment or prevention of inflammatory disease, the herbal compositions comprising at least a part of Coccinia indica.
2) Herbal compositions as claimed in claim 1, wherein said herbal compositions is selected from a group comprising whole Coccinia indica, extracts of Coccinia indica, crushed Coccinia indica, pulverized Coccinia indica, severed Coccinia indica, chemical constituents of Coccinia indica, and any combination thereof.
3) Herbal compositions as claimed in any of the preceding claims, wherein said herbal compositions further comprise additional herbs.
4) Herbal compositions as claimed in any of the preceding claims, wherein said herbal compositions further comprise additional herbs selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia, and any combination thereof.
5) Herbal compositions as claimed in any of the preceding claims, wherein the herbal compositions of the invention further comprises one or more of solvents, excipients, auxiliary agents, stabilizing agents, thickening agents, flavoring agents, fragrance, preservatives, fillers, coloring agents, and any combination thereof.
6) Herbal compositions as claimed in any of the preceding claims, wherein the herbal compositions of the invention treats or prevents inflammatory diseases selected from inflammatory joint diseases, rheumatoid arthritis, osteoarthritis, polyarthritis, gout, chronic inflammatory connective tissue diseases, lupus erythematosus, scleroderma, Sjorgen's syndrome, dermatomyositis, vasculitis, mixed connective tissue disease, tendonitis, synovitis, bacterial endocarditis, osteomyelitis and psoriasis, chronic inflammatory lung diseases, chronic respiratory disease, pneumonia, fibrosing alveolitis, chronic bronchitis, chronic obstructive pulmonary disease, bronchiectasis, emphysema, silicosis and other pneumoconiosis, tuberculosis, chronic inflammatory bowel, gastro-intestinal tract inflammatory diseases, chronic inflammatory demyelinating polyradiculoneuropathy, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, Guillan-Barre Syndrome and myasthemia gravis,
laminitis, laryngitis, chronic cholecystitis, Hashimoto's thyroiditis, chronic inflammation caused by an implanted foreign body in a wound, delayed onset muscle soreness, and any combination thereof.
7) Herbal compositions as claimed in any of the preceding claims, wherein the herbal compositions is in forms selected from a group comprising of injectable forms; solid tablets, pellets, granules, capsules, forms; oral usage form; topical application form; semi-solid form; gaseous form; and any combination thereof.
8) A process for preparing herbal compositions for treatment or prevention of inflammatory disease, comprises the steps of,
a) washing a part of Coccinia indica;
b) sieving the part of Coccinia indica; and
c) preparing pharmaceutically acceptable formulation thereof.
9) A process for preparing herbal compositions as claimed in any of the preceding claims, comprises the steps of,
a) washing a part of Coccinia indica and a part of an additional herb;
b) sieving the part of Coccinia indica and the part of the additional herb;
c) mixing the part of Coccinia indica and the part of the additional herb; and d) preparing pharmaceutically acceptable formulation thereof.
10) A process for preparing herbal compositions as claimed in any of the preceding claims, comprises the steps of,
a) washing a part of Coccinia indica and a part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia;
b) sieving the part of Coccinia indica and the part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia;
c) mixing the part of Coccinia indica and the part of additional herb selected from Acacia arabica, Diospyros peregrina, Mangifera indica, Arachis hypogeal, Sida cordifolia;
d) heating the above mixture in a vessel containing a solvent; and
e) preparing pharmaceutically acceptable formulation thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1040CH2011 | 2011-03-31 | ||
| IN1040/CHE/2011 | 2011-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012131650A1 true WO2012131650A1 (en) | 2012-10-04 |
Family
ID=46178584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2012/051580 WO2012131650A1 (en) | 2011-03-31 | 2012-03-31 | Herbal compositions of coccinia indica for treatment or prevention of inflammatory diseases |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012131650A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638138A (en) * | 2013-11-26 | 2014-03-19 | 宋爱民 | External traditional Chinese medicine preparation for treating achilles bursitis |
| CN109248295A (en) * | 2017-07-14 | 2019-01-22 | 民乐县科奇科技开发服务有限责任公司 | One group for treating the Chinese medicine of chronic cholecystitis |
-
2012
- 2012-03-31 WO PCT/IB2012/051580 patent/WO2012131650A1/en active Application Filing
Non-Patent Citations (11)
| Title |
|---|
| DANA SS, KAUL PN: "Indigenous technical knowledge in veterinary medicine among tribals", INDIAN J. ANIM. RES., vol. 34, no. 1, 2000, pages 56 - 59, XP002679314, ISSN: 0367-6722 * |
| GANESAN S ET AL: "Ethnoveterinary healthcare practices in southern districts of Tamil Nadu", INDIAN JOURNAL OF TRADITIONAL KNOWLEDGE, vol. 7, no. 2, 1 April 2008 (2008-04-01), RESOURCES NEW DELHI, NEW DELHI - INDIA, pages 347 - 354, XP018024000, ISSN: 0972-5938 * |
| GOPALAKRISHNAN V ET AL: "Antihepatotoxic activity of Coccinia indica", ANCIENT SCIENCE OF LIFE, vol. 21, no. 1, July 2001 (2001-07-01), pages 1 - 4, XP002679312 * |
| H. MUHAMED MUBARACK ET AL: "Activity of Some Selected Medicinal Plant Extracts Against Bovine Mastitis Pathogens", JOURNAL OF ANIMAL AND VETERINARY ADVANCES, vol. 10, no. 6, 1 June 2011 (2011-06-01), pages 738 - 741, XP055031896, ISSN: 1680-5593, DOI: 10.3923/javaa.2011.738.741 * |
| HUSSAIN A ET AL: "Antibacterial activity of the leaves of Coccinia indica (W. and A) Wof India", vol. 4, no. 5, 2010, pages 241 - 248, XP002679313, ISSN: 1992-0067, Retrieved from the Internet <URL:http://www.idosi.org/abr/4%285%29/1.pdf> [retrieved on 20120709] * |
| JEEVA 1 S ET AL: "Weeds of Kanyakumari district and their value in rural life", INDIAN JOURNAL OF TRADITIONAL KNOWLEDGE, vol. 5, no. 4, 1 October 2006 (2006-10-01), RESOURCES, NEW DELHI, NEW DELHI - INDIA, pages 501 - 509, XP018021460, ISSN: 0972-5938 * |
| JUNAID NIAZI ET AL: "Anti-inflammatory, analgesic and antipyretic activity of aqueous extract of fresh leaves of Coccinia indica", INFLAMMOPHARMACOLOGY, vol. 17, no. 4, 1 August 2009 (2009-08-01), pages 239 - 244, XP055031604, ISSN: 0925-4692, DOI: 10.1007/s10787-009-0010-3 * |
| KB SATAPATHY: "Ethnoveterinary practices in Jajpur district of Orissa", INDIAN JOURNAL OF TRADITIONAL KNOWLEDGE, vol. 9, no. 2, 1 April 2010 (2010-04-01), RESOURCES, NEW DELHI, NEW DELHI - INDIA, pages 338 - 343, XP018029304, ISSN: 0972-5938 * |
| NATAJARAN, SRI: "Kangayam Cattle Breed", BREED SAVIOUR AWARDS 2011 - LIVESTOCK KEEPER'S PROFILE, January 2011 (2011-01-01), pages 1-7, 36 - 37, XP002679072, Retrieved from the Internet <URL:http://www.sevango.in/pdf/breedsaviourawardees_2011.pdf> [retrieved on 20120627] * |
| P. VIVEKANANDAN: "Indigenous Veterinary Medicine", 2008, SUSTAINABLE AGRICULTURE AND ENVIRONMENTAL VOLUNTARY ACTION (SEVA), India, pages: 1-4, 28 - 29, XP002679311 * |
| WASANTWISUT E ET AL: "Ivy Gourd (Coccinia grandis Voigt, Coccinia cordifolia, Coccinia indica) in Human Nutrition and Traditional Applications", 1 January 2003, PLANTS IN HUMAN HEALTH AND NUTRITION POLICY, pages: 60 - 66, XP009160802 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638138A (en) * | 2013-11-26 | 2014-03-19 | 宋爱民 | External traditional Chinese medicine preparation for treating achilles bursitis |
| CN103638138B (en) * | 2013-11-26 | 2016-03-16 | 宋爱民 | The Chinese medicine for outer use for the treatment of achilles bursitis |
| CN109248295A (en) * | 2017-07-14 | 2019-01-22 | 民乐县科奇科技开发服务有限责任公司 | One group for treating the Chinese medicine of chronic cholecystitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6823622B2 (en) | Pharmaceutical composition containing crude drugs (land) | |
| WO2016082703A1 (en) | Preparation containing chlorogenic acid crystal form and use thereof | |
| CN110575432A (en) | A composition containing cannabidiol and its application in animal supplies | |
| BR112021016024A2 (en) | LIQUID PROPOLIS EXTRACT, ITS FORMULATION AND USE | |
| WO2012131732A1 (en) | A synergistic herbal extract composition for use in treating and preventing mastitis | |
| CN101708241B (en) | Medicinal composition for eliminating dampness and relieving itching | |
| WO2012131650A1 (en) | Herbal compositions of coccinia indica for treatment or prevention of inflammatory diseases | |
| CN101317904A (en) | Uses of smoked plum extract against virus, bacteria, mycoplasma or chlamydia of livestock and poultry | |
| CN103070813A (en) | Toothpaste applicable to chronic sinusitis patients | |
| GB2469577A (en) | Pharmaceutical composition based on a combination of plant materials | |
| CN117379484A (en) | Cattle and sheep pneumonia aerosol and preparation method and application thereof | |
| WO2012131643A1 (en) | Herbal compositions comprising pedilanthus tithymaloides for treatment prevention of gastrointestinal disorder | |
| CN101780205A (en) | Traditional Chinese medicine compound transdermal patch for treating mastitis of dairy cattle and preparation method thereof | |
| CN105770051A (en) | Pharmaceutical composition for veterinary use, feed additive, feed and application thereof | |
| Dahikar et al. | Pharmacokinetics of Withania somnifera (Ashwagandha) in healthy buffalo calves. | |
| WO2012131649A1 (en) | Herbal compositions comprising coldenia procumbens for treatment or prevention of udder sore | |
| JP2018188377A (en) | Pharmaceutical composition | |
| CN113577187A (en) | Anti-influenza traditional Chinese medicine composition, traditional Chinese medicine extract and preparation method and application thereof | |
| CN113456771A (en) | Traditional Chinese medicine composition for treating influenza and Yinlian antipyretic and detoxifying oral liquid containing traditional Chinese medicine composition | |
| WO2012131646A2 (en) | Herbal compositions for increase and improvement of milk yield in cattle | |
| WO2012131651A1 (en) | Herbal compositions for increase and improvement of milk yield in cattle | |
| WO2012131645A1 (en) | A herbal composition for treatment or prevention of ectoparasitic infestation | |
| US20140212478A1 (en) | Method for preventing and/or treating periodontal disease | |
| Das et al. | Antinociceptive, anti-inflammatory and hypoglycemic activities of Terminalia citrina leaves | |
| WO2012131641A1 (en) | Herbal compositions comprising vernonia cinerea with anti - bacterial anti - endoparasitic properties |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12724394 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12724394 Country of ref document: EP Kind code of ref document: A1 |